T cells are critical mediators of natural antitumor immunity which can be leveraged by TIL therapy or immune checkpoint blocking (ICB) therapy, such as antibodies directed against PD-1/L1 and CTLA-4 that established cancer immunotherapy as a pillar of cancer care a decade ago. This evidence concerns the gene CTLA4 and cancer.